Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
NATCOPHARM.NS
BuyUnloved QualityNATCO Pharma Limited · Healthcare · India · $1.6B · Avg Vol: $4M/d
72
StockRankGet insider-trade alerts
Q
69
V
64
M
34
P/E (TTM)
12.9x
ROE
15.4%
D/E
0.1x
Dividend %
0.5%
COMPANY DESCRIPTION
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally.
FINANCIAL SUMMARY (INR)
| Year | 2023 | 2024 | 2025 | 2026 | CAGR | TTM | 2027E | 2028E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27.0B | 39.8B | 44.1B | 40.4B | 14.5% | 34.8B | 32.1B | 35.6B | -6.2% |
| EPS (INR) | 39.18 | 77.34 | 105.26 | 79.20 | 26.4% | 63.91 | 42.28 | 47.37 | -22.7% |
| Shares | 182.5M | 179.1M | 179.1M | 179.1M | -1.8% | 179.1M | — | — | — |
| Debt | 1.8B | 3.7B | 2.8B | 7.1B | 59.5% | 7.1B | — | — | — |
| Equity | 48.7B | 58.5B | 76.1B | 92.2B | 23.7% | — | — | — | — |
| Op CF | 8.5B | 12.1B | 17.0B | 17.7B | 27.7% | 17.7B | — | — | — |
| Inv CF | -4.8B | -10.3B | -14.1B | -20.8B | — | — | — | — | — |
| Fin CF | -3.6B | -2.5B | -2.1B | 3.0B | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-11.6%
SMA 50SMA 200
Close
$8.69
RSI (14)
16.7
52W High
$12.88
From 52W High
0.7%
SCORE BREAKDOWN
Quality
69
ROIC
12.3%77.0
ROE
15.4%82.4
GP/Assets
26.0%55.8
Op. Margin
19.0%81.4
FCF/Assets
12.4%90.6
Piotroski
431.0
Int. Cover
24.8x72.8
D/E Ratio
0.08x65.9
Current Ratio
3.01x55.3
Value
64
P/E (TTM)
12.9x80.6
EV/EBITDA
12.5x58.1
P/FCF
11.0x81.8
P/B
1.6x71.0
P/S
4.3x45.5
Div Yield
0.5%16.8
Momentum
34
52W High %
67%44.7
RS 6M
-16%44.1
SMA 50/200
0.96x46.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-26%14.0
Q Growth
-57%8.9
FUNDAMENTALS
Market Cap
$1.6B
P/E (Forward)
17.4x
Gross Margin
82.6%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NATCOPHARM.NS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NATCOPHARM.NS | NATCO Pharma Limited(you) | $1.6B | 72 | Buy |
| SHILPAMED.NS | Shilpa Medicare Limited | $2.0B | 69 | Buy |
| APLLTD.NS | Alembic Pharmaceuticals Limited | $1.7B | 84 | Strong Buy |
| JUBLPHARMA.NS | Jubilant Pharmova Limited | $1.7B | 60 | Hold |
| CAPLIPOINT.NS | Caplin Point Laboratories Limited | $2.2B | 86 | Strong Buy |
| AARTIPHARM.NS | Aarti Pharmalabs Limited | $829M | 65 | Buy |
| ALIVUS.NS | Alivus Life Sciences Limited | $1.8B | 91 | Strong Buy |
| VIYASH.NS | Viyash Scientific Limited | $1.2B | 88 | Strong Buy |
| ERIS.NS | Eris Lifesciences Limited | $1.9B | 55 | Hold |
| GRANULES.NS | Granules India Limited | $2.3B | 87 | Strong Buy |
Peer medians: ROE 11.8% · P/E 42.8x · Gross margin 59.4%